(Q35612108)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

16 November 2019

review article

1 reference

title

Review article: current management of chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

16 November 2019

1 reference

1 reference

George Papatheodoridis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

16 November 2019

author name string

S J Hadziyannis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

16 November 2019

language of work or name

English

0 references

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

16 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

16 November 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

16 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

16 November 2019

page(s)

25-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14687164%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B: an important public health issue

16 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Hepatitis B: global importance and need for control

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Clinical relevance of hepatitis B viral mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Diagnosis and management of pre-core mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Treatment of HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Treatment options for chronic hepatitis B not responding to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Alcohol use and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Suppressing hepatitis B without resistance--so far, so good

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01810.X